Neurogene (NASDAQ:NGNE) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $70.00 price target on the stock.
Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome [Yahoo! Finance]
Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome
Neurogene to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)